unknown
Stage
4
Investors
About
Avidity Biosciences develops targeted RNA therapeutics using its Antibody Oligonucleotide Conjugates (AOC) platform to treat rare muscle diseases by addressing underlying genetic causes.
Explore Avidity Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.